Abstract 4578: Development of a rapid clinical grade assay to detect and monitor secondary <i>KIT</i> mutations in circulating free DNA (cfDNA) for personalization of targeted therapy for gastrointestinal stromal tumors (GIST)
Adrián Mariño‐Enríquez(Harvard University Press), Yanan Kuang(Dana-Farber Cancer Institute), Pasi A. Jänne(Harvard University), Chandrajit P. Raut(Dana-Farber Cancer Institute), Cloud P. Paweletz(Massachusetts General Hospital), Grace A. Heavey(Dana-Farber Cancer Institute), Suzanne George(Dana-Farber Cancer Institute), Julianna Supplee(Dana-Farber Cancer Institute), Jonathan A. Fletcher(Harvard University), George D. Demetri(American Society of Clinical Oncology)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k